ASX 200 Insider Trades: Directors bought and sold these 7 stocks last week
Ebos and Sonic Healthcare insiders continued to buy the dip, while an NRW insider is selling into recent strength.
Source: iStock
Mentioned
Welcome back to the Insider Trades series – a weekly summary of on-market ASX 200 director transactions valued at more than $10,000. The below trades have all taken place between 3 and 9 October 2025. Directors have up to 5 business days to notify the ASX of their trades.
Top ASX 200 Insider Buys
Code | Company | Date | Director | Price | Value |
|---|---|---|---|---|---|
Ebos Group | 7/10/25 | $26.00 | $52,000 | ||
Sonic Healthcare | 3/10/25 | $21.72 | $21,720 | ||
Orora | 6/10/25 | $2.06 | $10,300 |
Interesting takeaways
Ebos Group has attracted buying interest from another non-executive director following a 14.6% selloff on the day of its FY25 result (27 August). While the results broadly met expectations, FY26 EBITDA guidance of 3% growth was below Macquarie expectations of 8%. The stock has since fallen to its lowest level since early 2021. However, Citi analysts noted on 18 September that "consensus has also seen downward revisions to estimates, which we think are now probably done. Expected market growth in the various subsegments of healthcare still looks somewhat opaque, but we think, if anything, there is potentially some room for upside into FY26/27, especially if Animal Care (5% of revenue but more of EBITDA) outperforms."
Sonic Healthcare has similarly seen directors step in to buy the dip, with six separate insiders collectively purchasing around $525,000 worth of shares in recent weeks. The catalyst was a weak FY25 result on 21 August, with NPAT 3% below expectations, pathology EBITDA margin 60 bps under consensus at 17.7%, and FY26 guidance also missing forecasts. This triggered a 12.8% one-day selloff, followed by a further 14.5% decline since. While Citi analysts acknowledged "some bright spots in the print with double-digit CER growth in the UK and the radiology division, both of which we expect to remain strong," they remained cautious on US revenue growth (the company's second-largest market) after a disappointing FY25 relative to larger peers. In their 18 September note, they maintained a Neutral rating with a $24.00 target price.
Top ASX 200 Insider Sells
Code | Company | Date | Director | Price | Value |
|---|---|---|---|---|---|
Wisetech Global | 9/10/25 | $87.16 | $50,008,050 | ||
Generation Development Group | 8/10/25 | $7.15 | $2,003,123 | ||
NRW Holdings | 8/10/25 | $4.73 | $945,381 | ||
Perseus Mining | 9/10/25 | $4.96 | $620,000 | ||
Perseus Mining | 9/10/25 | $4.96 | $520,800 |
Interesting takeaways
Wisetech Founder and Executive Chairman Richard White continuing to offload shares. He has sold approximately $290 million (around 2.5% of his total holdings) over the past two months. The stock plunged 11.9% on its FY25 results (27 August) after EBITDA missed guidance and FY26 forecasts disappointed on both revenue and margins. Shares have fallen a further 18% since and trading at levels seen since April 2025. Despite the near-term pain, several analysts remain constructive on the E2open acquisition's ability to expand the company's competitive moat, alongside large freight forwarder contract wins and the scaling of new products like CTO and AI-enabled workflows.
NRW Holdings recorded its first insider sell since early 2022, following a powerful 44% rally since its FY25 result on 19 August. Macquarie analysts described it as "a solid result with Civil & METS outperforming Mining that faced several headwinds," noting that the "outlook remains positive with strong work in hand, active tendering environment, and upside risk to group margins." However, the main catalyst for recent gains was the 3 September acquisition of Fredon Industries, which drove the stock 5.2% higher to near year-to-date highs. Analysts widely viewed the deal as both strategic and immediately EPS accretive, with enthusiasm around the attractive 5.2x EV/EBIT multiple relative to peers. A key highlight was the creation of a fourth operating segment, EMIT, which expands NRW Holdings into high-growth sectors including energy transition, data centres, defence, and health.
